At baseline, days 7 and 14, and days 14 and 21 after treatment, mass cytometry and immunocytological examination revealed that intraperitoneally injecting H101 significantly reduced tumor cell density and boosted dendritic cell and CD8+ T cell densities (130). The gene discussed is CD8A; the disease is neoplasm.